CTO: Trials vs. Real-World

Percutaneous coronary intervention of chronic total occlusions (CTO) is currently indicated for symptom improvement, as studies have inadequate randomization of data which hinders the assessment of hard outcomes. However, patient inclusion in randomized controlled trials has been challenging, especially for highly symptomatic and higher risk patients. This causes a selection bias in randomized studies on CTOs.

CTO: Trials vs Mundo Real

The purpose of this meta-analysis was to evaluate the differences between patients with CTOs in the real world vs. those who were included in randomized studies.

Outcomes were evaluated in terms of procedural success, in-hospital mortality, acute myocardial infarction (AMI), major cardiovascular events (MACE), and cardiac tamponade. Procedural success was defined as technical success (<30% residual stenosis with TIMI 3 flow) without MACE.

In this study, the analysis included 6 randomized controlled studies comparing CTA to CTO vs. medical treatment (N = 1047), 10 CTO-dedicated registries (N = 76,467), and 5 national registries (N = 110,349). Most patients in the randomized studies were men and had a trend of lower comorbidities such as diabetes, hypertension, peripheral artery disease, prior AMI, prior CTA, and prior myocardial revascularization surgery. In addition, these patients underwent procedures with longer fluoroscopy time and greater use of contrast material.

Procedural success was significantly lower in the national registries compared with the randomized studies (63.9% vs. 84.5%, relative difference = 24.4%). However, randomized studies had a higher risk of in-hospital events, including death (1.3% vs. 0.6%, relative difference = 52.3%), MACE (7.9% vs. 1.5%, relative difference = 81.0%), AMI (5.9% vs. 1.0%, relative difference = 83.1%), and cardiac tamponade (0.9% vs. 0.3%, relative difference = 66.7%).

Read also: Longitudinal Deformation of a Stent with the POT Technique.

When comparing patients from randomized studies vs. CTO-dedicated registries, patients included in the studies had shorter CTOs and low J-CTO scores (2.0-1.1 vs. 2.3-1.2, relative difference = 13.0%). Although procedural success was similar between both groups (84.5% vs. 81.4%), patients included in the studies presented a higher risk of in-hospital events (death, MACE, AMI, and cardiac tamponade).

Conclusion

Patients included in the randomized studies had less risk profile and less injury complexity than real-world registries. Current evidence from randomized controlled studies may not be representative of real-world patients and should be interpreted with this limitation. Procedures performed by surgeons specialized in CTOs have significantly more success and fewer complications than those performed by surgeons that are not specialized in CTOs.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Comparative Analysis of Patient Characteristics in Chronic Total Occlusion Revascularization Studies Trials vs Real-World Registries.

Reference: Michael Megaly, MD  et al J Am Coll Cardiol Intv 2022;15:1441–1449.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...